Companies › Nacuity Pharmaceuticals
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Ophthalmology, Metabolic and endocrine; next expected readout Apr 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| N-Acetylcysteine Amide (NPI-001) Cystine-depleting agent; reduces intracellular cystine accumulation | – | Phase 3 | Retinitis Pigmentosa (RP); Cystinosis | Apr 2029 |
| NPI-002 Intravitreal Implant Intravitreal implant for cataract progression delay | – | Phase 1 | Cataract | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05994534 | N-Acetylcysteine Amide (NPI-001) | Phase 1 | Cystinosis | Metabolic and endocrine | May 2026 |
| NCT05026632 | NPI-002 Intravitreal Implant | Phase 1 | Cataract | Ophthalmology | Sep 2026 |
| NCT07710196 | N-Acetylcysteine Amide (NPI-001) | Phase 3 | Retinitis Pigmentosa (RP) | Ophthalmology | Apr 2029 |
No annotated target.
–
Biojiva Bausch & Lomb Huons Sling Therapeutics PolyActiva
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.